Triple

T22458037
Position Surface form Disambiguated ID Type / Status
Subject ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals E555162 entity
Predicate relatedTo P37 FINISHED
Object ICH S5 Reproductive Toxicity Testing Guidelines NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ICH S5 Reproductive Toxicity Testing Guidelines | Statement: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: ICH S5 Reproductive Toxicity Testing Guidelines
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S5 Reproductive Toxicity Testing Guidelines]
  • A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
    ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
  • B. Experimental Toxicology and ZEBET
    Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
  • C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
    ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Toxicology in the 21st Century program
    The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: ICH S5 Reproductive Toxicity Testing Guidelines
Target entity description: The ICH S5 Reproductive Toxicity Testing Guidelines are international standards that outline how to evaluate the potential effects of pharmaceuticals on fertility, embryo-fetal development, and pre- and postnatal development to support safe drug use in humans.
  • A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
    ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
  • B. Experimental Toxicology and ZEBET
    Experimental Toxicology and ZEBET is a specialized section of Germany’s Federal Institute for Risk Assessment focused on experimental toxicology and the development and promotion of alternative methods to animal testing.
  • C. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
    ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
  • D. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
    ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
  • E. Toxicology in the 21st Century program
    The Toxicology in the 21st Century program is a U.S. research initiative that uses modern high-throughput and computational methods to improve the prediction of chemical toxicity and reduce reliance on traditional animal testing.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e11e51fdec8190adfdf9f8a6362221 completed April 16, 2026, 5:37 p.m.
NER Named-entity recognition batch_69f15b7d00208190955a70e2c22d25a4 completed April 29, 2026, 1:14 a.m.
Created at: April 16, 2026, 8:48 p.m.